R1 RCM — Merger or Acquisition (January 2022)
21 slides from R1 RCM's merger presentation, Jan 10, 2022
Slide 1: The Strategic Partner to the Provider Industry
JANUARY 10, 2022 The Strategic Partner to the Provider Industry Exhibit 99.2
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation includes information that may constitute “forward-looking statements,” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking
Slide 3: Disclaimer: Additional Information and Where to Find It
Disclaimer Additional Information and Where to Find It In connection with the proposed transaction and plan of merger (the “Transaction Agreement”) by and among R1 RCM, Inc. (“R1”), Project Roadrunner Parent Inc., a wholly owned subsidiary of R1 (“New Pubco”), Project Roadrunner Merger Sub Inc., a w
Slide 4: Disclaimer: Financial Projections
Disclaimer Financial Projections All financial projections in this presentation are forward-looking statements that are based on assumptions that are inherently subject to significant uncertainties and contingencies, many of which are beyond R1’s control. No independent registered public accounting
Slide 5: Standalone 2022 R1 Guidance
~$10B of NPR in contracting, expected to be signed in early February 2022 We plan to update guidance after closing the Cloudmed acquisition and signing the new contract R1’s Board of Directors has increased the Company’s share repurchase authorization to $500M Standalone 2022 R1 Guidance $M 2021E 20
Slide 6: Presenters
Lee Rivas Chief Executive Officer Presenters Joseph Flanagan President Chief Executive Officer Rachel Wilson Executive Vice President Chief Financial Officer & Treasurer
Slide 7: Transaction Overview
Timing and Approvals Expected to close Q2 2022 Subject to R1 shareholder approval, regulatory approval and customary closing conditions Management and Board Joe Flanagan will be CEO and Lee Rivas will be President of the combined company Three directors nominated by Cloudmed shareholders will join R
Slide 8: Transforming Revenue Performance Across Care Settings and Payment Models
All Revenue Cycle Phases Order to Intake Care to Claim Claim to Payment All Payment Models Fee-for-service Patient Self-pay Value-based All Care Settings Ambulatory Acute Post-Acute Transforming Revenue Performance Across Care Settings and Payment Models Solutions address the full spectrum of needs
Slide 9: Cloudmed Overview
Cloudmed Overview Proof Points Comparison to R1 Capability Highlights 500M patient records annually Ranked #1 by KLAS Health Systems contracted: 47 of Top 50 / 87 of Top 100 $800B NPR installed base 10x annually 6x total rules 12K total rules Ranked #1 by KLAS R1 installed base: $42B end-to-end $200
Slide 10: Powerful Combination of Market-leading Platforms
Leading data and analytics-driven revenue intelligence platform Leading E2E technology-driven platform to manage healthcare provider revenue Powerful Combination of Market-leading Platforms Market-leading tech-enabled platform Strategic partner of choice to providers Unlocks significant TAM & accele
Slide 11: Strong Financial Profile and Meaningful Synergies
Unlocks TAM for modular offerings Meaningfully diversifies customer base Accelerates digitization, leveraging data and technology Preserves flexibility to invest in the business 16% revenue CAGR from 2022 – 2026 30%+ Adjusted EBITDA margin in 2026 Moderately accretive to R1’s EPS and cash flow per s
Slide 12: Cloudmed Overview
Cloudmed Overview R1 | ocloudmed
Slide 13: Strategic Partner to Providers
Strategic Partner to Providers We help healthcare providers get paid for the care they deliver COMPLEX PROBLEM PERSISTENT CHALLENGES POWERFUL SOLUTION Up to 5% revenue leakage $100B problem Large scale data problem Reimbursement complexity Business model aligned with customer success 3-5x customer R
Slide 14: Leading Revenue Intelligence Platform
Leading Revenue Intelligence Platform Analyze large volumes of clinical and financial data Identify missed opportunities Deliver revenue to customers What We Do Platform Core Components Scalability Cloud-based Data Architecture Flexibility Implementation Predictive Analytics Intelligent Automation M
Slide 15: Scaled Platform with Proven Results
Scaled Platform with Proven Results Ranked #1 by KLAS REVENUE GROWTH 20%+ NET REVENUE RETENTION 108% Average duration Of top 10 customers 15 YEARS HEALTH SYSTEMS AS CUSTOMERS 47 OF TOP 50 NET PATIENT REVENUE COVERED $800B PATIENT INTERACTIONS 500M SCALED PLATFORM PROVEN RESULTS HEALTH SYSTEMS SERVED
Slide 16: Summary
Summary ign R1 | ocloudmed
Slide 17: Pro Forma Financial Profile
Pro Forma Financial Profile $M 2022E Revenue $1,680 $446 $2,126 % YoY Growth 14% 23% 2022E Adj. EBITDA $395 $191 $6711 % Adj. EBITDA margin 24% 43% 32% Note1: Includes anticipated $85M of cost synergies by year-end 3, R1 plans to update guidance after completion of transaction to reflect part-year c
Slide 18: Revised Outlook
Revised Outlook Prior Outlook Revised with Cloudmed NPR Growth 10-12% 12-14% Modular Growth - ~20% Adjusted EBITDA Growth 12-15% 17%+ Medium-Term Margin Target 25% 30%+ Long-Term Margin Target 30% 35%+
Slide 19: Summary Highlights
Summary Highlights Combination Provides… Market leading “Platform” fueled by automation and data Resulting In… Acceleration of growth by unlocking full market potential Aligned economics solving complex provider challenges Trusted partner of choice Flexible engagement models (end-to-end and modular)
Slide 20: Appendix
R11 ocloudmed Appendix \
Slide 21: Use of Non-GAAP Financial Measures
Use of Non-GAAP Financial Measures In order to provide a more comprehensive understanding of the information used by R1’s management team in financial and operational decision making, the Company supplements its GAAP consolidated financial statements with certain non-GAAP financial performance measu